Name | Number of supported studies | Average coverage | |
---|---|---|---|
CD16-positive, CD56-dim natural killer cell, human | 6 studies | 19% ± 3% | |
natural killer cell | 5 studies | 18% ± 2% | |
non-classical monocyte | 4 studies | 24% ± 7% | |
conventional dendritic cell | 3 studies | 29% ± 12% | |
ciliated cell | 3 studies | 22% ± 5% | |
dendritic cell | 3 studies | 30% ± 11% |
Insufficient scRNA-seq data for expression of FBXO6 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
prostate | 100% | 630.60 | 245 / 245 | 100% | 33.04 | 500 / 502 |
thymus | 100% | 503.64 | 652 / 653 | 100% | 29.18 | 603 / 605 |
liver | 100% | 655.00 | 226 / 226 | 100% | 30.97 | 404 / 406 |
lung | 100% | 732.83 | 578 / 578 | 99% | 41.98 | 1149 / 1155 |
pancreas | 100% | 506.11 | 328 / 328 | 99% | 26.09 | 177 / 178 |
breast | 100% | 479.60 | 459 / 459 | 99% | 38.64 | 1108 / 1118 |
esophagus | 100% | 636.66 | 1445 / 1445 | 99% | 30.36 | 181 / 183 |
ovary | 100% | 385.91 | 180 / 180 | 99% | 34.30 | 425 / 430 |
uterus | 99% | 413.36 | 169 / 170 | 99% | 41.68 | 454 / 459 |
bladder | 100% | 535.00 | 21 / 21 | 98% | 38.86 | 495 / 504 |
intestine | 100% | 480.14 | 966 / 966 | 97% | 29.52 | 513 / 527 |
skin | 100% | 518.91 | 1806 / 1809 | 97% | 36.29 | 458 / 472 |
stomach | 100% | 532.49 | 359 / 359 | 97% | 31.73 | 277 / 286 |
kidney | 100% | 475.53 | 89 / 89 | 95% | 23.83 | 856 / 901 |
brain | 100% | 568.09 | 2637 / 2642 | 90% | 19.46 | 634 / 705 |
adrenal gland | 100% | 713.70 | 258 / 258 | 70% | 9.56 | 161 / 230 |
adipose | 100% | 435.53 | 1204 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 29.78 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 81.71 | 29 / 29 |
muscle | 100% | 711.63 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 873.96 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 45.13 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 40.04 | 1 / 1 |
peripheral blood | 100% | 1109.91 | 928 / 929 | 0% | 0 | 0 / 0 |
blood vessel | 99% | 343.81 | 1320 / 1335 | 0% | 0 | 0 / 0 |
heart | 97% | 366.94 | 838 / 861 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0016567 | Biological process | protein ubiquitination |
GO_0006986 | Biological process | response to unfolded protein |
GO_0031146 | Biological process | SCF-dependent proteasomal ubiquitin-dependent protein catabolic process |
GO_0006281 | Biological process | DNA repair |
GO_0006508 | Biological process | proteolysis |
GO_0036503 | Biological process | ERAD pathway |
GO_0000077 | Biological process | DNA damage checkpoint signaling |
GO_0006516 | Biological process | glycoprotein catabolic process |
GO_0019005 | Cellular component | SCF ubiquitin ligase complex |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0044322 | Cellular component | endoplasmic reticulum quality control compartment |
GO_0061630 | Molecular function | ubiquitin protein ligase activity |
GO_0030246 | Molecular function | carbohydrate binding |
GO_0005515 | Molecular function | protein binding |
Gene name | FBXO6 |
Protein name | F-box protein 6 F-box only protein 6 (F-box protein that recognizes sugar chains 2) (F-box/G-domain protein 2) |
Synonyms | FBG2 FBS2 FBX6 |
Description | FUNCTION: Substrate-recognition component of some SCF (SKP1-CUL1-F-box protein)-type E3 ubiquitin ligase complexes. Involved in endoplasmic reticulum-associated degradation pathway (ERAD) for misfolded lumenal proteins by recognizing and binding sugar chains on unfolded glycoproteins that are retrotranslocated into the cytosol and promoting their ubiquitination and subsequent degradation. Able to recognize and bind denatured glycoproteins, which are modified with not only high-mannose but also complex-type oligosaccharides. Also recognizes sulfated glycans. Also involved in DNA damage response by specifically recognizing activated CHEK1 (phosphorylated on 'Ser-345'), promoting its ubiquitination and degradation. Ubiquitination of CHEK1 is required to ensure that activated CHEK1 does not accumulate as cells progress through S phase, or when replication forks encounter transient impediments during normal DNA replication. . |
Accessions | J3KQ72 ENST00000376753.9 ENST00000449067.1 Q9NRD1 |